Back to today’s briefing

Story perspectives

FDA Approves AstraZeneca's $4,900 Breast Cancer Drug Datroway

1/20/2025

29 7

Summary

Story summary

AstraZeneca and Daiichi Sankyo celebrate a major milestone as their groundbreaking drug, Datroway, gains FDA approval for advanced HR-positive, HER2-negative breast cancer. Priced at $4,900 per vial, this innovative treatment promises to dramatically lower the risk of disease progression, offering hope to many. The companies are eyeing ambitious peak sales of $5 billion.

1 of 1

Story summary

AstraZeneca and Daiichi Sankyo celebrate a major milestone as their groundbreaking drug, Datroway, gains FDA approval for advanced HR-positive, HER2-negative breast cancer. Priced at $4,900 per vial, this innovative treatment promises to dramatically lower the risk of disease progression, offering hope to many. The companies are eyeing ambitious peak sales of $5 billion.